why choose us

First received: March 11, 2024

Clinical Trial: Effect of Telitacicept on Antibody Titers in Primary APS Patients

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Antiphospholipid Syndrome (APS)

Study Type: INTERVENTIONAL


Official Title: A Single Center, Randomized Controlled, Open Label Trial Exploring the Regulatory Effect of Telitacicept on Antibody Titers in Primary Antiphospholipid Syndrome Patients Carrying High-risk Antiphospho

Brief Summary: The purpose of this study is to evaluate the regulatory effect of Telitacicept on antibody titers in primary antiphospholipid syndrome patients carrying high-risk antiphospholipid antibody profiles.

Read more